Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 34Rectal Neoplasms 22Triple Negative Breast Neoplasms 16Stomach Neoplasms 16Colorectal Neoplasms 13Neoplasm Metastasis 9Adenocarcinoma 9Pancreatic Neoplasms 8Esophageal Neoplasms 8Adenocarcinoma Of Esophagus 7Neoplasms 5Nasopharyngeal Carcinoma 5Biliary Tract Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Carcinoma, Non-Small-Cell Lung 4Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Spinocerebellar Degenerations 2Ovarian Neoplasms 2Neoplasm, Residual 2Carcinoma 2Anus Neoplasms 2Advanced Solid Tumour 2Somatostatinoma 1Solid Tumors 1Resectable Colon Cancer 1Rectal Cancer Patients 1Peritoneal Neoplasms 1Pathologic Complete Response 1

Interventions

irinotecan sucrosofate 1camrelizumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Cancer Patients × Capecitabine × 90 days × Clear all
NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
44 enrolled
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡